Table 3. Treatments and outcomes of patients with COVID-19 during hospitalization.
| All patients (n = 199) | Non-severe (n = 166) | Severe (n = 33) | |
|---|---|---|---|
| Treatments | |||
| Antiviral therapy | 199 (100) | 166 (100) | 33 (100) |
| Lopinavir/ritonavir | 192 (96.5) | 163 (98.2) | 31 (93.9) |
| Arbidol | 72 (36.2) | 54 (32.5) | 18 (54.4) |
| Ribavirin | 36 (18.1) | 33 (19.9) | 3 (9.1) |
| Oseltamivir | 11 (5.5) | 7 (4.22) | 4(12.1) |
| Interferon inhalation | 105 (52.8) | 87 (52.4) | 18 (54.5) |
| Antibiotics therapy | 96 (48.2) | 68 (41) | 28 (84.8) |
| Chinese medicine | 80 (40.2) | 66 (39.8) | 14 (42.4) |
| Corticosteroid | 34 (17.1) | 17 (10.2) | 17 (51.5) |
| Intravenous immunoglobulin | 29 (14.6) | 13 (7.8) | 16 (48.5) |
| Oxygen therapy | 83 (41.7) | 56 (33.7) | 27 (81.8) |
| Nasal cannula | 70 (35.2) | 55 (33.1) | 15 (45.5) |
| Non-invasive mechanical ventilation (high-flow nasal cannula or face mask) | 8 (4.0) | 1 (0.6) | 7 (21.2) |
| Invasive mechanical ventilation | 4 (2.0) | - | 4 (12.1) |
| ECMO | 1 (0.5) | - | 1 (3.0) |
| Complications | 15 (7.5) | 0 | 15 (45.5) |
| ARDS | 9 (4.5) | 0 | 9 (27.3) |
| Respiratory failure | 8 (4.0) | 0 | 8 (24.2) |
| Multiple systemic organ failure | 3 (1.5) | 0 | 3 (9.1) |
| Shock | 2 (1.0) | 0 | 2 (6.1) |
| Admission to intensive care unit | 14 (7.0) | 0 | 14 (42.4) |
| Complicated with bacterial infection | 38 (19.1) | 16 (9.6) | 22 (66.7) |
| Deterioration | 16 (8.0) | 0 | 16 (48.5) |
| Prognosis | |||
| Survival and discharge | 198 (99.5) | 166 | 32 (97) |
| Death | 1 (0.5) | 0 | 1 (3.0) |
| Days from first positive to last negative RT-PCR | 15 (11–21) | 15 (11–20) | 18 (14–23) |
| Days from admission to discharge | 19 (14–25) | 19 (15–24) | 24 (20.5–28) |
The Data are n (%) or median (IQR). ECMO = extracorporeal membrane oxygenation.